|Articles|June 6, 2013

PD-1 Inhibitors are a game changer

Author(s)Guest

Michael Wong, melanoma oncologist and CURE advisory board member, explains how recent studies are targeting the PD-1 pathway and describes why there is so much excitement surrounding this new class of immunotherapy.


Related to this article

Image of of hot flashes
Hot flashes are common during and after breast and prostate cancer treatment. Here is how hormone treatments compare with the nonhormonal medicines, therapies and comfort steps that national guidelines list, and why the right choice depends on your cancer.
mammogram
Long-term Kisqali data, a new targeted drug, blood tests and AI are among the topics to watch at the 2026 San Antonio Breast Cancer Symposium.